Right now, as these words stroll into your visual cortex wearing little sentence-shaped hats, your brain is doing more than reading. It is sorting signals, tuning attention, remembering what a "cortex" is, and quietly taking out molecular trash so cells do not become the biological equivalent of a junk drawer with Wi-Fi.

That trash system matters more than it sounds. A new study in The Journal of Clinical Investigation looks at Skraban-Deardorff syndrome, a rare neurodevelopmental condition caused by too little working WDR26 protein. It can involve developmental delay, intellectual disability, seizures, autistic-like behaviors, walking differences, and distinctive facial or dental features. Clinicians knew the gene was involved. The annoying part, because biology enjoys withholding the plot until episode seven, was how one missing dose of WDR26 could scramble brain development.

Meet WDR26, the Cellular Stage Manager

WDR26 helps run part of the cell's protein disposal machinery: the CTLH E3 ubiquitin ligase complex. Translation: it helps tag certain proteins for recycling by the proteasome, the cell's tiny wood chipper for proteins that have overstayed their welcome. Ubiquitin tags are molecular sticky notes saying, "Please remove this before it causes a meeting."

Xu and colleagues built mice with one working copy of Wdr26, similar to the haploinsufficiency seen in people. Mice with no working copies did not survive embryonic development, which is the cell's unsubtle way of saying this gene is not decorative. Mice with one copy lived, but they showed learning and memory problems, social behavior differences, motor deficits, greater seizure susceptibility, and occasional craniofacial and dental abnormalities. The model did not capture every human detail, because mice remain mice and refuse clinical questionnaires, but it reproduced enough of the syndrome to be useful Xu et al., 2026.

The Protein That Wouldn't Leave

The sharpest clue was a protein called RUNX1T1. Normally, WDR26 helps keep RUNX1T1 levels in check by promoting its ubiquitination and degradation. When WDR26 runs low, RUNX1T1 hangs around too long, like a party guest explaining cryptocurrency after everyone else has switched to water.

That extra RUNX1T1 appears to disturb MAP2, a protein involved in dendrites, the branch-like parts of neurons that receive incoming messages. Dendrites are not passive wires. They are tiny decision trees, signal mixers, and cellular gossip hubs. MAP2 helps shape their internal scaffolding, so changing MAP2 levels can plausibly affect how neurons connect and adapt.

This fits a broader theme: brain wiring depends on protein timing. Too little, too much, too early, too late - all of it can matter. Recent work connects ubiquitin-system mutations to neurological disease Zenge and Ordureau, 2024, while MAP2 has been reviewed as more than just a dendrite marker DeGiosio et al., 2022. Dendritic dysfunction is also a recurring suspect in neurodevelopmental disorders Nelson and Bender, 2021.

The Rescue Attempt, With Asterisks

Here is the part that makes the study especially intriguing. The researchers reduced Runx1t1 in newborn Wdr26 mice using an AAV-shRNA approach. That lowered MAP2 overexpression and improved behavioral deficits. In mouse-world terms, that is meaningful. In human-world terms, it is a lead, not a treatment plan. Neonatal gene delivery in mice is not the same as treating children, and nobody should read this as "we solved Skraban-Deardorff syndrome over lunch."

They also tested risperidone, an antipsychotic already used clinically in some contexts. In these mice, it improved cognitive and social measures and appeared to increase WDR26 levels. Repurposed drugs can move faster than brand-new therapies. Still, risperidone has real side effects and mouse behavior assays are not miniature human clinics with tails.

Still, the result gives researchers a targetable pathway: WDR26 to RUNX1T1 to MAP2. That is better than waving vaguely at "brain development," which is scientifically accurate but about as helpful as telling someone their car problem is "transportation."

Why This Matters Beyond One Rare Syndrome

Rare disease studies often teach us general biology. Skraban-Deardorff syndrome may be uncommon, but the machinery involved here - protein degradation, transcriptional control, dendritic architecture - is the stuff every developing brain uses.

For families, the practical impact is not immediate, and honesty matters. Current care remains supportive: seizure management, developmental therapies, feeding support, behavioral care, and genetics-guided follow-up. CHOP describes diagnosis by genetic testing and individualized care CHOP. NORD similarly frames WDR26-related disorder as rare, variable, and currently managed by symptoms rather than a cure NORD.

But this mouse model changes the research conversation. It gives scientists a living system for testing timing, dose, and therapies. If the findings reproduce and expand, future work might ask whether boosting WDR26, reducing RUNX1T1, or normalizing MAP2-related dendritic changes can help specific symptoms. The brain will still be absurdly complicated, obviously. It did not become a three-pound prediction machine by being easy. But now there is a clearer trail, and for rare disease research, that is not nothing.

References

1. Xu X, Zhou Y, Xu S, et al. Wdr26 insufficiency causes Skraban-Deardorff syndrome-like neurodevelopmental deficits in mice. Journal of Clinical Investigation. 2026. DOI: 10.1172/JCI195537.
2. Gross A, Muller J, Chrustowicz J, et al. Skraban-Deardorff intellectual disability syndrome-associated mutations in WDR26 impair CTLH E3 complex assembly. FEBS Letters. 2024;598(9):978-994. DOI: 10.1002/1873-3468.14866. PMCID: PMC7616460.
3. Zenge C, Ordureau A. Ubiquitin system mutations in neurological diseases. Trends in Biochemical Sciences. 2024;49(10):875-887. DOI: 10.1016/j.tibs.2024.06.011.
4. DeGiosio RA, Grubisha MJ, MacDonald ML, McKinney BC, Camacho CJ, Sweet RA. More than a marker: potential pathogenic functions of MAP2. Frontiers in Molecular Neuroscience. 2022;15:974890. DOI: 10.3389/fnmol.2022.974890.
5. Nelson AD, Bender KJ. Dendritic integration dysfunction in neurodevelopmental disorders. Developmental Neuroscience. 2021;43(3-4):201-221. DOI: 10.1159/000516657.

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.